Compare Pfizer Inc (PFE) vs Vertiv Holdings Co (VRT) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Vertiv (VRT) trades at $291.67, up 0.73% today, with a bearish technical signal but strong fundamental momentum. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected on July 29, 2026. Revenue and net income are projected to grow in 2026, supported by robust demand for AI data center infrastructure, including recent expansions in cooling solutions manufacturing.

The outlook is positive due to AI-driven growth and a $15 billion order backlog, though high valuation multiples and technical weakness pose risks. Analyst consensus is strongly bullish with a $402.92 price target, but investors should monitor execution on growth targets and competitive pressures in the data center equipment market.